Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$411.0K-84.25%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marc H. Hedrick
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 28
- Beta
- 1.47
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -57.08
Financials
Revenue
$411.0K-84.3%Net Income
$-9.01MEBITDA
$-8.91MFree Cash Flow
$-7.63MEPS (diluted)
$-1.33Shares Outstanding (diluted)
6.77M+825890.9%Operating Expenses
$9.32MCash & Debt
$8.59MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.21M | $-22.39M | $-7.19 |
| 2024 | $5.82M | $-12.98M | $-48.75 |
| 2023 | $4.91M | $-13.32M | $-106000.00 |
| 2022 | $224.0K | $-20.27M | $-288750.00 |
| 2021 | $0.00 | $-13.40M | $-444500.00 |
| 2020 | $303.0K | $-8.24M | $-697500.00 |
| 2019 | $7.00M | $-10.89M | $-3101250.00 |
| 2018 | $2.98M | $-12.63M | $-32617500.00 |
| 2017 | $6.41M | $-22.69M | $-131345500.00 |
| 2016 | $11.38M | $-22.05M | $-240000000.00 |
| 2015 | $11.66M | $-18.74M | $-374898500.00 |
| 2014 | $7.60M | $-37.37M | $-1007767000.00 |
| 2013 | $12.20M | $-26.18M | $-984097750.00 |
| 2012 | $14.50M | $-32.28M | $-1312154500.00 |
Valuation
CNSYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+7.14%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·5d ago·Positive
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
View source ↗ - Newsglobenewswire.com·6d ago·Negative
… after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Test) and the expansion of the CNSide testing menu.
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
Cerenome to Hold CNSide® Business Update Call on September 30, 2026 HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), today announced that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m.
View source ↗ - Newsglobenewswire.com·14d ago·Negative
…o Approximately 158 Million Covered Lives HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay.
View source ↗ - Newsglobenewswire.com·20d ago·Positive
…mmercial Sales, CNSide Diagnostics Division HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and healt…
View source ↗ - Newsglobenewswire.com·26d ago·Negative
…rovided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repaym…
View source ↗ - Newszacks.com·52d ago·Negative
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates Cerenome (CNSY) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.25 per share a year ago.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.
View source ↗
Earnings
Thu, Oct 15(in 9 days)
Consensus estimate $-0.98 per share
Typical surprise -23.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-1.31 vs $-0.88miss
- Fri, May 15$-1.05 vs $-0.85miss
- Thu, Mar 12$-0.83 vs $-0.80miss
- Thu, Oct 30$-1.00 vs $-0.50miss
- Thu, Aug 14$0.50 vs $-2.25beat
- Fri, May 30$-29.75 vs $-6.20miss
Estimates and results for CNSY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNSY officers and directors.
No open-market trades in the recent filings. All 22 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
22 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CNSY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.